Effectiveness of Zoledronic Acid in Reducing Pediatric Fracture Rates
Overview
This retrospective cohort study of 102 children and young adults with primary and secondary skeletal fragility demonstrated that zoledronic acid (ZA) treatment significantly reduced annualized fracture rates. Both long bone and spine fractures decreased, with benefits observed across diverse etiologies of bone fragility.
Background
Pediatric skeletal fragility arises from heterogeneous causes including primary genetic disorders like osteogenesis imperfecta and secondary conditions such as neuromuscular disease or bone-toxic therapies. Management typically begins with nutritional optimization and weight-bearing activities, but pharmacologic options are limited by lack of FDA-approved osteoporosis medications for children. Bisphosphonates, particularly intravenous zoledronic acid, are increasingly used off-label due to their potent antiresorptive effects and demonstrated safety profile. However, evidence for fracture reduction efficacy in pediatric populations has been limited.
Data Highlights
Parameter
Pre-Treatment Median (IQR)
Post-Treatment Median (IQR)
P Value
Overall Fracture Rate (fractures/year)
0.6 (0.3-1.1)
0 (0-0.4)
< .001
Primary Skeletal Fragility Fracture Rate
1.0 (0.6-1.5)
0.3 (0-0.6)
< .001
Secondary Skeletal Fragility Fracture Rate
0.5 (0.1-0.8)
0 (0-0.3)
< .001
Key Findings
Zoledronic acid treatment reduced median annual fracture rates from 0.6 to 0 fractures per year overall (P < .001).
Significant fracture rate reductions occurred in both primary (e.g., osteogenesis imperfecta) and secondary skeletal fragility groups.
Fracture reductions were observed for long bone fractures alone and when combined with spine fractures.
Median treatment duration was 1.8 years, supporting sustained efficacy over time.
ZA was administered intravenously with individualized dosing and frequency based on clinical judgment.
Clinical Implications
Zoledronic acid is an effective pharmacologic option to reduce fracture risk in children and young adults with diverse causes of skeletal fragility. Its use should be considered as part of a comprehensive management plan including nutritional optimization and monitoring. Individualized dosing protocols and biochemical monitoring are important to maximize safety and efficacy.
Conclusion
Zoledronic acid treatment is associated with significant and sustained reductions in fracture rates among pediatric patients with both primary and secondary bone fragility. These findings support its role in clinical practice for fracture prevention in this vulnerable population.
References
Study Authors/CHOP/2010-2017 -- Effectiveness of Zoledronic Acid in Reducing Fractures Among Children With Primary and Secondary Bone Fragility
